Fresh From the Bench: Latest Federal Circuit Court Cases
Contributed by Schwabe Williamson & Wyatt. Originally published on Patexia; republished here as part of the LexDana archive.
CASE OF THE WEEK
In re Ron Maatita, Appeal No. 2017-2037 (Fed. Cir. Aug. 20, 2018)
In an appeal from an examiner’s rejection, the Federal Circuit addressed a rare issue concerning the application of 35 U.S.C. § 112 to design patents.
The application contained a single claim directed to an ornamental design for the bottom of an athletic shoe sole, which was rejected based on the applicant’s use of a single, two-dimensional plan view. The examiner found, and the PTAB affirmed, that the two-dimensional drawing left the design open to multiple interpretations regarding the depth and contours of the claimed elements, rendering the claim not enabled and indefinite under Section 112.
The Federal Circuit reversed, first observing that because design patent claims are limited to what is shown in the application drawings, the “definiteness” and “enablement” requirements are similar and can ordinarily be addressed together in design patent cases. The Court distinguished cases finding non-enablement and indefiniteness where irreconcilable inconsistencies existed between application drawings, or between drawings and the claim language. Rather, the Court held that the only question in Maatita’s case was whether the single representation sufficiently described the design. Observing that the definiteness inquiry is driven by whether the claim provides sufficient notice as to what will or will not infringe, the Court held that “a design patent is indefinite under § 112 if one skilled in the art, viewing the design as would an ordinary observer, would not understand the scope of the design with reasonable certainty based on the claim and visual disclosure.”
Written by: Scott D. Eads and Nika F. Aldrich, Schwabe, Williamson & Wyatt
Contributors: Jason Wrubleski and Karri Kuenzli Bradley, Ph.D.
More insights
Federal Circuit Affirms Invalidation of Patent for Lack of Enablement of Claims Directed to a Method of Treating a Patient with a Unit Dosage in Wyeth Llc v Astrazeneca Pharmaceuticals Lp
Written by : Eric Furman, Ph.D. and Ashley C. Morales Key Takeaway: Federal Circuit invalidates patent claims directed to a method for treating non-small cell lung cancer through administration of “a unit dosage” of an irreversible epidermal…
When About Becomes Indefinite Federal Circuit Provides Guidance for Life Science Patent Applications Regarding Limits of Approximation in Enviro Tech v Safe Foods
Written by : Jason J. Jardine and Kenneth O. Aruda, Ph.D. Key Takeaway: The term “about” remains useful in biotech and pharmaceutical claims, but only if the patent provides objective guidance about what the term means. Absent that guidance,…
When Any Patent Means No Patent Federal Circuit Reverses Non Specific Verdict
Written by : Brian C. Barnes and Sophia F. Zahn OLLNOVA TECHNOLOGIES LTD. v. ECOBEE TECHNOLOGIES ULC [OPINION] Before Chen , Cunningham, and Stark. Appeal from the United States District Court for the Eastern District of Texas. Summary : A verdict form…